Charles River Laboratories Net Income/Loss 2010-2025 | CRL

Charles River Laboratories net income/loss for the twelve months ending March 31, 2025 was $0.459B, a 56.28% decline year-over-year.

  • Charles River Laboratories annual net income/loss for 2024 was $0.025B, a 94.74% decline from 2023.
  • Charles River Laboratories annual net income/loss for 2023 was $0.48B, a 2.48% decline from 2022.
  • Charles River Laboratories annual net income/loss for 2022 was $0.493B, a 23.51% increase from 2021.

Charles River Laboratories Net Income/Loss 2010-2025 | CRL

  • Charles River Laboratories annual net income/loss for 2024 was $0.025B, a 94.74% decline from 2023.
  • Charles River Laboratories annual net income/loss for 2023 was $0.48B, a 2.48% decline from 2022.
  • Charles River Laboratories annual net income/loss for 2022 was $0.493B, a 23.51% increase from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$146.6B
CVS Health (CVS)$81.9B
Elevance Health (ELV)$77B
Cencora (COR)$57.2B
DiDi Global (DIDIY)$24.2B
Natera (NTRA)$21.9B
Labcorp Holdings (LH)$20.9B
BioMerieux (BMXMF)$16.9B
EUROFINS SCIENT (ERFSF)$13.7B
CochLear (CHEOY)$12.8B
Solventum (SOLV)$12.8B
ICON (ICLR)$12.2B
Revvity (RVTY)$12B
Viatris (VTRS)$10.7B
Medpace Holdings (MEDP)$9.3B
Avantor (AVTR)$9.3B
Sonic Healthcare (SKHHY)$8.9B
HealthEquity (HQY)$8.2B
Caris Life Sciences,�Inc (CAI)$6.7B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$4.9B
BrightSpring Health Services (BTSG)$3.6B
Sotera Health (SHC)$3.3B
Surgery Partners (SGRY)$2.8B
Alignment Healthcare (ALHC)$2.6B
Organon (OGN)$2.6B
Concentras Parent (CON)$2.6B
GeneDx Holdings (WGS)$2.4B
Ardent Health (ARDT)$2B
Progyny (PGNY)$2B